Menu

CME Corner

Active Programs

Improving Outcomes in Advanced Gastric Cancer: The Latest Updates in Treatment Strategies and Clinical Research

An estimated 26,370 Americans will be diagnosed with gastric cancer in 2016. Most patients with gastric cancer present with advanced or metastatic disease, for which the prognosis is poor. The 5-year survival rate of patients with all stages of gastric cancer in the United States is approximately 29% and drops into the single digits for patients with stage III or IV disease. However, recent advanc ...

  • Mobile + Online on QuantiaMD Mobile + Online on QuantiaMD
  • ACCME

Multidisciplinary Care of Patients with Relapsed/Refractory Multiple Myeloma

The treatment landscape for multiple myeloma (MM) is rapidly evolving. This activity will examine tailored treatment approaches for patients with relapsed/refractory multiple myeloma. ...

  • Online Presentation Online Presentation
  • ACCME

Updates on Molecular Testing in NSCLC

Oncologists have new options when treating advanced NSCLC. The use of molecular profiling to define subgroups of patients most likely to experience clinical benefit from novel targeted therapies has been endorsed by both ASCO and the National Comprehensive Cancer Network (NCCN).This activity will examine the role of molecular biomarkers in patients with advanced NSCLC. ...

  • Mobile + Online on QuantiaMD Mobile + Online on QuantiaMD
  • ACCME

Patient-Centered Care in Advanced Prostate Cancer

Recommended treatment options for prostate cancer vary based on disease severity and life expectancy, with traditional approaches including active surveillance, surgery, radiation therapy, chemotherapy, and androgen deprivation therapy (ADT). Prostate cancer that progresses despite ADT is known as castration-resistant prostate cancer (CRPC). Until recently, the standard of care for CRPC patients w ...

  • Mobile + Online on QuantiaMD
  • ACCME

Expired Programs

A Case Study in Monitoring and Managing Response and Resistance in CML

Chronic myeloid leukemia (CML) is a myeloproliferative disorder of the bone marrow, accounting for 15% of adult leukemias. Targeted therapy with tyrosine kinase inhibitors (TKIs) has dramatically improved 10-year overall survival for patients with CML from 20% to 80%-90%. To determine the best treatment approach for patients with CML, clinicians must thoroughly understand how to monitor treatment ...

  • Mobile + Online on QuantiaMD Mobile + Online on QuantiaMD
  • ACCME

Improving Patient Outcomes in Chronic Myeloid Leukemia: Monitoring and Managing Response and Resistance

NOTE: This activity was presented as a live visiting faculty grand rounds series beginning on October 29, 2015. Participants who received credit for attending any of the live presentations are not eligible to receive credit for this online release. Chronic myeloid leukemia (CML) is a myeloproliferative disorder of the bone marrow, accounting for 15% of adult leukemias. Targeted therapy with ty ...

  • Online Presentation Online Presentation
  • ACCME

Targeting B-Cell Lymphomas: The Latest Updates in Therapies, Practice Strategies, and Clinical Research

The standards of care in treatment for non-Hodgkin lymphomas (NHL) are evolving as new therapies receive FDA approval and new evidence provides insight into optimal evidence-based approaches. Several key cellular pathways that drive malignant B-cell development have recently been identified and validated, leading to the development of therapies targeting these pathways. Agents targeting the B-cell ...

  • Online Presentation
  • ACCME
Main Menu
EDITOR'S PICKS